Compare
Abbott Laboratories vs Dexcom (ABT vs DXCM)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and Dexcom (DXCM) +34.0%; so far this year the figures are -12.3% and +19.6%.
Abbott Laboratories is the larger company by market value, about 6.4 times the size of Dexcom.
On trailing earnings, ABT trades at 40.9 times and DXCM at 31.3 times.
Revenue grew +10.0% at ABT and +13.0% at DXCM over the last year.
ABT yields 2.29%. DXCM pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | DXCM | |
|---|---|---|
| Price | $109.93 | $79.41 |
| 1-day | -3.23% | -5.98% |
| YTD | -12.26% | +19.65% |
| 1 year | -11.73% | +33.96% |
| 3 years | +15.70% | -15.64% |
| Market cap | $190.4B | $29.6B |
| P/E | 40.9 | 31.3 |
| P/S | 3.95 | 5.80 |
| P/B | 3.73 | 11.68 |
| Revenue growth | +10.00% | +13.00% |
| EPS growth | -66.20% | +41.10% |
| Gross margin % | 56.9 | 63.4 |
| Net margin % | 9.7 | 19.4 |
| ROE % | 9.2 | 39.1 |
| Debt / equity | 0.61 | 0.00 |
| FCF yield % | 3.5 | 3.7 |
| Dividend yield % | 2.29 | — |
| Beta | 0.06 | 0.70 |
| RSI (14) | 58.5 | 42.8 |
| Technical rating |